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Currently, there is no single, Europe-wide regulation of biomedical research using human samples and data. Instead,
the law that applies spans a number of areas of law, such as data protection, clinical trials, and tissue regulation. In
the absence of harmonized regulation, there is considerable scope for national legal variation. This article analyzes the
legislative frameworks that apply to biobanking activities to identify differences in legal requirements between the
BioSHaRE-EU project countries: Finland, France, Germany, the Netherlands, Norway, and the United Kingdom. This
article highlights the primary role of consent and accompanying governance mechanisms, such as research ethics
committee oversight, which enable consent exemptions in the context of research. Our analysis identifies a complicated
legal landscape, whereby broadly similar provisions are contained in varied sources of law in each jurisdiction. The
challenge for researchers is locating the applicable legal provisions within each national legal framework.
Introduction
B iomedical research in Europe relies on the collec-tion of human tissue and the subsequent extraction,
manipulation, and linkage of associated data. The regulation
of this activity is largely carried out at a national level as
currently there is no single, Europe-wide piece of regulation
for biomedical research that applies to both human samples
and data. Research Ethics Committees (RECs) play a crucial
role in determining whether research should go ahead within
the different national legal frameworks. Some countries have
chosen to sign and ratify the international Council of Europe
Convention on Human Rights and Biomedicine1 and its
protocols relating to research uses of human tissue, but
member states, such as the United Kingdom, have not.
Instead, the law that applies to biomedical research at the
European level spans a number of areas of law, such as data
protection (Data Protection Directive 95/48 EC and the new
General Data Protection Regulation) clinical trials (Regula-
tion EU No. 536/2014) and tissue regulation (Tissues and
Cells Directive 2004/23/EC). This year, two directives that
apply to tissue within Europe came into force,2,3 but neither
apply to tissue that is used for research purposes. The regu-
latory landscape is undergoing considerable reform with the
introduction of the Clinical Trials Regulation (Regulation EU
No. 536/2014) and the General European Data Protection
Regulation (GDPR), perhaps signaling a move toward a
greater degree of harmonization between member states (al-
though with a ‘‘margin of appreciation’’ for member states as
to how these are implemented).
The EU Parliament, Commission, and Council have now
agreed to a General Data Protection Regulation that will
harmonize aspects of data protection across Europe. This
regulation will become effective in 2018, and in the interim,
the Data Protection Directive and existing national laws still
apply. As a regulation, the GDPRwill be directly binding and
carries over many of the same principles as the Data Protec-
tion Directive. For research and biobanking, broad consent is
generally acceptable, where it is not possible to be specific
about the purposes of the research. Member states will also be
able to legislate for processing of health data for research
purposes without consent, so long as safeguards are in place,
and the regulation requires safeguards, such as pseudonymi-
zation, to be used, where possible, in research.
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In the absence of uniform European regulation of bio-
banks, research participants or donors to biorepositories may
consent using different documents in different jurisdictions
for different types of research. This has implications for
further research because it prevents the creation of a single
harmonized data set that can be used easily across borders.
Equally, not all participants across Europe will receive the
same level and type of information on potential uses of their
samples and data and any risks involved. BioSHaRE-EU is
one of a number of collaborative projects aiming to har-
monize and standardize biobanking across Europe. Other
European and international examples include P3G Public
Population Project in Genomics and Society, BBMRI-ERIC
EU (Biobanking and BioMolecular resources Research
Infrastructure), and International Cancer Genome Consortium
(ICGC). This article will comparatively analyze the legislative
frameworks for consent and biobanking activity in the six
original BioSHaRE-EU countries, which each having well-
established biobanks: Finland, France, Germany, the Nether-
lands, Norway, and the United Kingdom.
Methods
It would be logical to presume that having national legal
frameworks governing this activity would lead to consid-
erable differences in the legal requirements across Europe.
To test this assumption, we analyzed the legislative frame-
works that applied to biobanking activities in Finland,
France, Germany, the Netherlands, Norway, and the United
Kingdom to identify the differences between them. Bio-
banks based in these countries are part of the BioSHaRE-EU
project, which aims to develop tools to enable large-scale
analysis, involving a number of biobanks located in differ-
ent EU member states.4 These countries were the original
members of the BioSHaRE-EU project and now have well-
established biobanks. As such, we have chosen to focus our
investigation on these five countries, and the legislation in
each of these jurisdictions applies to consent for (1) re-
search, (2) biobanking, (3) the use of samples, and (4) data
for research purposes.
To conduct our comparative legal analysis, representative
experts from each jurisdiction conducted analysis of their
jurisdictional legislative frameworks and applied information
about the relevant country-specific provisions to the issue of
consent. Where there is jurisdictional regulation relating to
specific consent, we include details of such provisions; for the
remaining countries, there is an absence of specific consent
requirements, and the alternative approach will be described.
Results
Our study showed that there was remarkable uniformity
in the consent processes for samples and data, but in each of
these countries, this was achieved using different legal
means, which will be detailed below.
Discussion
Finland
Finland enacted the Medical Research Act in 2000 to
implement the EU Clinical Trials Directive and set norms
for all medical research.5 The Medical Research Act sets
rigorous criteria for informed consent and requires, among
other things, ethics committee approval before research
taking place (s. 3). The act was seen, inter alia, to hinder the
feasibility of broad consent for medical research. To im-
prove the research framework, Finland enacted specific
legislation for biobanking6 in 2013, which provides the legal
framework for the collection, storage, and processing of
samples and sets out the rights of individuals and arrange-
ments necessary to protect personal information.7
Under this Biobank Act, a biobank’s entitlement to pro-
cess samples is primarily based on a broad and informed
consent: The participant receives extensive information on
the nature and objectives of the biobank and can track the
use of samples and data (s. 11). A special feature of the act
is to allow the transfer of old clinical samples and research
samples into a biobank following a special procedure noti-
fying individuals and providing an opt-out to inclusion of
material in the biobank. Samples and data in a Finnish
biobank shall be shared within the research community, and
the results shall enrich the biobank.
The Act on the Medical Use of Human Organs and Tis-
sues8 provides additional exemptions for the secondary use
of clinically obtained samples for medical research and to be
used in biobanks without consent (s. 20). Secondary use
may take place, subject to an ethical review, if the person is
deceased. Sometimes a permit from the National Super-
visory Authority for Welfare and Health is required. This
will be granted only if an REC has also issued a favorable
opinion on the matter (s. 21a).
For the processing of personal data, the Personal Data
Act9 is a lex generalis and will apply unless specific pro-
visions are found elsewhere in the law. Thus, the Personal
Data Act complements other acts. This act directly im-
plemented the provisions of the Data Protection Directive
95/46/EC. Under the act, consent is generally required under
section 8, but processing is lawful for scientific research if
‘‘the research cannot be carried out without identifying the
person and the consent of the data subjects cannot be ob-
tained owing to the quantity of the data, their age or another
comparable reason’’ [para. 14 (1)]. These provisions for data
mirror those of the directive and therefore are in conformity
with requirements across Europe. The Biobank Act is re-
garded as lex specialis, and thus, many of its provisions
prevail over the more general Personal Data Act.
France
Under the French legal framework for the storage and use
of human biological samples, several pieces of legislation
must be respected: the bioethics law,10 the law on bio-
medical research,11 and the law regarding data protection.12
The legislation does not refer to biobanks per se (the term
‘‘biobank’’ does not exist in any legal text) but instead to the
collection of biological samples.13 In addition to this defi-
nition, the Public Health Code describes two kinds of ac-
tivities that could be developed by researchers collecting
samples: collection of samples by researchers for the needs
of their own research programs and collection of samples for
transfer (i.e., biobanking).
Researchers must obtain informed consent from the donor
of the biological material before starting any research ac-
tivity. Written consent must be obtained based on clear in-
formation, and the consent can always be withdrawn
(Article L 1211-2 of the Public Health Code). Multiple
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consents have to be given for the process of biobanking: for
the storage, handling, use, and research purpose for which
the participant has given its tissues and cells and associated
data. Although samples and data are covered by two pieces
of legislation, the consent has to mention the processing of
associated personal data for research purposes.
Alternatively, for previously collected samples, a specific
procedure has been set up in the bioethics law to facilitate
their use (Article LL1211-2, Public Health Code) through
the implementation of an opt-out procedure. This opt-out
procedure does not apply when genetic analyses are per-
formed. In this case, a written informed consent is required.
The institutions in charge of the legal and ethical assess-
ments of sample collections are, on the one hand, the
Committee of Persons’ Protection (CPP, Ethics committee)
and, on the other hand, the Ministry of Research. Both must
be consulted, and they assess the conformity of the research
protocol with research/bioethics laws.
Health data, including genetic data, are considered as
sensitive data according to the definition of the Data Pro-
tection Act (art. 8-1) and in accordance with the 95/46/EC
Directive. Regarding the processing of genetic information, in
order for it to be lawful, it is necessary to obtain the express
consent of the individuals whose data are to be collected, as
stated in Art 56: ‘‘where the research requires the collection
of identifying biological samples, the informed and express
consent of data subjects must be obtained prior to the im-
plementation of data processing.’’ In principle, collection,
processing, and transfer abroad of such data are forbidden,
except if the data subject has given his or her express consent
or for necessary medical research. The transfer of personal
data abroad is restricted to foreign countries, ensuring a
sufficient level of protection. The French National Data
Protection Supervisory Authority is called ‘‘Commission
Nationale Informatique et Liberte´’’ (CNIL); it is in charge of
the supervision of the personal data collection and uses.
Germany
There is no specific legislation concerning biomedical
research as a whole within Germany, but instead, there are
three different pieces of legislation that in combination
cover this area. These are (1) the Act on Medical Devices
(Medizinproduktegesetz [MPG]) adopted in 1994, (2) the
fifth Amendment of the Act on Pharmaceutical Products
(Arzneimittelgesetz) adopted in 1995, and (3) the Code of
Deontology (‘‘A¨rztliche Berufsordnung’’), which, in the
German states, is a legally binding instrument. All these
instruments have requirements that research should be re-
viewed by an REC, which is also a requirement of the Eu-
ropean Clinical Trials Regulations.
In addition, there are more general constitutional rights
under the German Basic Law (Grundgesetz) pertaining to
matters, such as individual personality, dignity, and integ-
rity.14 This provision requires the prior consent of an indi-
vidual for the donation of tissue for research purposes,15–17
which should be informed by the ‘‘purpose, significance,
and implications of the encroachment,’’ that is, whether the
samples are taken for the specific purpose of research and
biobanking.15 However, consent is not necessary for
downstream use of lawfully procured tissue as between
biobanks and researchers. This is because tissue, when
separated from the body, is treated as a form of property
under German law.15,17,18 In this framework, the transfer of
the tissue between parties is treated by way of contractual
arrangements, such as assignments and licenses, as any
other form of property.19 The Gesetz u¨ber Qualita¨t und Si-
cherheit von menschlichen Geweben und Zellen (Act on
Quality and Safety of Human Tissues and Cells, also known
as Human Tissue Act, BGBl. I 2007, 1574) implemented the
EU Directive 2004/23/EC20 in German law (17, p. 92).
The law in Germany differs from other European countries
as it often has higher protections than those stipulated in Eu-
ropean law. An example of this is the consent requirements for
the use of data in research. Consent needs to be given inwriting
unless special circumstances warrant another form. The EU
Data Protection Directive is implemented in a federal act
(BDSG) and fragmented across individual state and canonical
legislation in Germany.21 These instruments distinguish be-
tween public and private entities and do not apply to anon-
ymized data. The BDSG definition of sensitive data expressly
includes health data [s. 3(9)]. All data use ought to take place
under the umbrella of valid informed consent. Derogations
from this principle are possible in cases where the scientific
value of the exercise outweighs the individuals’ right to opt out
or where research cannot otherwise not be undertaken at all or
only at disproportionate effort [ss. 13(2) and 28(6)]. This is a
unique feature of the German law as it is a higher standard than
the requirements of 95/46/EC Directive. It is possible that this
‘‘special circumstance’’ may exist in the field of scientific re-
search [s. 28(6)4], but generally, consent shall be recorded in
writing, where special categories of personal data, such as
health data, are collected, processed, or used [s. 3(9)].
While there are no biobank-specific laws that operate in
Germany, an opinion on human biobanks was published by
the German Ethics Council in June 2010.15 There has been a
public discussion for a number of years on the benefits of
implementing specific biobank legislation, but to date, this
has not happened. In 2015, a biobank law for Germany was
drafted to address the deficit in the law, but currently, this is
just a proposal.22
Netherlands
In the Netherlands, there is no general regulation for bio-
medical research or specific regulation for biobanking,23
although the Dutch Council of the Federation of Medical
Scientific Societies (Federatie Van Medisch Wetenschappe-
lijke Verenigingen) has set out a Code of Conduct for med-
ical research. Instead, there is a detailed legal framework,
spanning a number of sources, for use of tissue (including
sperm, ova, and fetal tissue) and data. As with other juris-
dictions, there is the requirement that research must be ap-
proved by an REC.
In terms of samples, the general principle within the Dutch
Civil Code, (BurgerlijkWetboek), via provisions contained in
the Medical Treatment Contracts Act (Wet op de genees-
kundige behandelingsovereenkomst), is that consent is re-
quired. However, these regulations permit the use of human
tissue for ‘‘medicostatistical or other medicoscientific re-
search.’’ There are two conditions for such research taking
place: the ‘‘patient,’’ from whom the tissue was extracted,
must not have objected to the research and any resulting data
from the use of this tissue must not be capable of being
‘‘traced back to the person from whom they originated’’ (Art.
7:467). The Human Tissue Requirements Decree of 2006
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(Eisenbesluit Lichaamsmateriaal) also sets out requirements
with respect to the safety and quality of human tissues used in
medical treatment. This legislation also contains provisions
regarding data derived from samples, including institutional
responsibilities to ensure that data accessible by third parties,
such as genetic information, can no longer be traced to
individuals (Art. 9.1).
Like all other member states in Europe, the Netherlands
has implemented the provisions of the Data Protection Di-
rective 95/46/EC. The Personal Data Protection Act of 2000
(Wet bescherming persoonsgegevens) implements the EU
Directive into Dutch law. Personal data can be used for the
purpose of scientific research, without the data subject’s
consent, so long as (1) the research ‘‘serves a public inter-
est,’’ (2) is necessary for such research, (3) would be ‘‘im-
possible or would involve a disproportionate effort to ask for
express consent,’’ and (4) that ‘‘sufficient guarantees’’ are
provided to ensure there are no disproportionately adverse
effects on individuals’ privacy [Art. 23(2)].
Norway
In common with Finland, Norway also has specific legis-
lation for the regulation of medical research. In Norway, the
research use of both personal health data and samples is reg-
ulated by the same legislative instrument: The Health Re-
search Act (Helseforskningsloven—hereafter the ‘‘HRA’’).24
This single comprehensive piece of legislation contains spe-
cific provisions relating to research biobanks and research
involving human biological material and requires the storage
and processing of material in research biobanks to be carried
out with respect for the donor’s wishes. Patients must be in-
formed in advance that their biological material may be used
for research and they have the option to refuse to be involved
in research on human biological material. Moreover, an
electronic register has been established with the patients who
have stated that they do not wish their biological material to
be used for research (s. 28). Under the act, unless specific legal
authority or another valid legal basis exists, the collection,
storage, and processing of human biological material and data
for research purposes require consent by the donor, which
should be (1) voluntary, (2) express, and (3) informed (s. 12).
If previously collected material and data are subject to a
different, wider, or new use, which does not fall within the
scope of the original consent, then new voluntary, express,
and informed consent must be obtained.
However, it is not always strictly necessary to gain the
explicit consent of the data subject to process personal
health data for research purposes if the specific conditions
set out in the Health Research Act are met (s. 35). The REC
may decide that such data can or shall be handed over by
health personnel for use in research if, and only if, the re-
search in question is of significant interest to society and the
data subject’s welfare and integrity are ensured. The REC
may also specify further conditions for the use of the data
and the rules on confidentiality pursuant to section 7 of the
act will apply to the recipient party accordingly.
Moreover, where it is impossible or very difficult to ob-
tain new consent, the Regional Committee for Medical and
Health Research Ethics (REC) may grant an exemption from
this requirement (s. 15). The REC may specify conditions
for the new or changed use. Uses of anonymized material do
not require consent (s. 20). Any person who has given his or
her consent pursuant to sections 11–13 may withdraw such
consent at any time. In this case, the person who gave such
consent has the right to require that the biological material,
as well as any health and personal data collected together, is
destroyed, erased, or returned unless the material has been
anonymized or is already being used in scientific work.
United Kingdom
Like the Netherlands and Germany, the United Kingdom
adopts a similarly fragmented legislative approach to the
regulation of tissues and data in research. Unlike Finland
and Norway, there is no single piece of regulation for bio-
medical research or biobanking. The distinction between
tissue and data that are found in other jurisdictions is also a
feature of U.K. legislation.
In relation to tissue, the Human Tissue Act 2004 regulates
the removal, storage, use, and disposal of human tissue for
scheduled purposes via the specifically created regulatory
body, the Human Tissue Authority (HTA). One of the HTA
statutory functions under the act is to issue Codes of Prac-
tice, which should give guidance to researchers interested in
carrying out activities regulated by the HTA. Even if non-
compliance with these Codes of Practice is not in itself an
offense under the HT Act, it could influence licensing de-
cisions made by the HTA.
Whereas the data protection legislation provides for
processing of data for research purposes without consent in
certain circumstances, the Human Tissue Act holds the
‘‘appropriate consent’’ of individuals as a core feature.
Obtaining valid consent presupposes that there is a process
in which individuals (including their families where ap-
propriate) may discuss the issue fully, ask questions, and
make an informed choice. That said, tissue from living
donor that has been properly anonymized and has received
appropriate REC approval can be used in research without
the consent of the donor.25 A unique feature of the U.K.
legal framework regarding access to samples is that an HTA
license is required whenever relevant material is held for
research purposes (s. 16 HTA). However, there are some
exceptions, where the license is not required.
The Data Protection Act of 1998 implements the EU Data
Protection Directive and regulates the ‘‘processing of per-
sonal data,’’ also allowing processing for research purposes
(s. 33). In the United Kingdom, it is not necessary to gain
the explicit consent of the data subject to process sensitive
data for research purposes if conditions set out in a Pro-
cessing of Sensitive Personal Data Order26 are met. This
requires the processing to be in the substantial public in-
terest, necessary for research purposes, that it does not
support measures or decisions with respect to any particular
data subject otherwise than with the explicit consent of that
data subject and that it does not cause, nor is likely to cause,
substantial damage or substantial distress to the data subject
or any other person.27
Conclusions
Each of the BioSHaRE-EU project countries has provisions
that apply to the use of samples and data for research pur-
poses, but these are contained in different sources of law in
each jurisdiction. This is because there is no single Euro-
pean legislative instrument equivalent to the European Data
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Protection Directive 45/46/EC that regulates the use of hu-
man tissue in research or biomedical research in general.
The result is that across the member states, a range of na-
tional laws apply to the use of human tissue in research,
including different licensing regimes, individual rights,
biobank-specific laws, and research-specific laws.
The key difference is the legal basis for consent provisions,
which may be found in constitutional law (Germany), Civil
Code (the Netherlands), statute (Finland and Norway), or a
combination of legislation and regulations (the United
Kingdom and France). Some countries rely on general law to
cover medical research and biobanking combined with more
specific codes of practice or opinions from national bodies
(Germany, the Netherlands, and the United Kingdom). A
common trend is to maintain different legal regimes for
samples and data. However, Finland and Norway have each
implemented law that unifies consent requirements for data
and samples. French legislation cross-references between
biomedical research instruments and data protection rules.
Consent is the primary justification and requirement for
research or biobank use of samples across these BioSHaRE-
EU states. For example, the Finnish Biobank Act places
consent at the heart of biobank regulation and the primary
basis for use of samples by biobanks (s. 11). This law ex-
plicitly grants individuals the right to change their consent to
types of research at any time (s. 12) and contains provisions
for biobanks to maintain a ‘‘consent register’’ to record any
restrictions on use of individual samples [s. 22(3)]. However,
almost all nations provide exemptions to the requirement for
consent for research use of samples, provided certain condi-
tions are met. The laws of the Netherlands, France, Norway,
the United Kingdom, and Finland provide legal pathways for
the transfer of clinical samples to biobanks for medical re-
search without consent. In all the BioSHaRE-EU countries,
REC approval is required for all research that is carried out on
human beings as within Europe they are ‘‘the key decision-
makers in reviewing and allowing a research protocol.’’28
However, there are different REC approval procedures across
the BioSHaRE-EU jurisdictions,29 and the only common
feature is that the REC or, in France, theMinistry of Research
must approve the research plan before any research is un-
dertaken. In the literature, it has been highlighted that ‘‘broad
consent’’ is effectively ‘‘consent for governance’’ by others as
judgments about appropriate uses of data and samples ‘‘often
fall to researchers, advisory boards, or RECs, who must make
decisions on behalf of research participants.’’30 The discre-
tionary nature of REC judgments has the potential to amplify
existing local differenceswithin this fragmented legal system.
Of the BioSHaRE-EU jurisdictions analyzed in this arti-
cle, only Germany lacks an exemption to the requirement
for consent to research using samples, although if consent
has been provided to initial research use, then secondary use
of samples in Germany is instead governed by property law,
contracts, and licenses. German law’s insistence on consent
for research use of samples also contrasts with the position
for research using personal data within the terms of the EU
Data Protection Directive since all five BioShaRE-EU ju-
risdictions allow the use of identifiable personal data for
research purposes without consent in certain circumstances.
Our analysis has illustrated the importance of consent in
biobanking and medical research across the BioShaRE-EU
jurisdictions as consent requirements and regulatory over-
sight of secondary research without consent are stipulated in
the law of every BioShaRE-EU country. The key difference
across the countries is where these requirements are found in
the national legal framework. Some nations set them out in
biobank-specific legislation; for the others, they are con-
tained in more general areas of law. As a result, there are
some minor variations in consent requirements, in particular
Finland and Norway have more specific biobank legislation
and more sophisticated consent models. The implications of
the GDPR and the provision for derogation between member
states may mean that this fragmented approach is likely to
continue. Therefore, the challenges for researchers are to
identify the appropriate jurisdiction and locate the applicable
legal provisions on consent within each country. Platforms,
such as P3G31 and hSERN,32 are important in helping re-
searchers access and navigate this complex legal landscape.
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